Dear Biostate AI investors, followers, and collaborators,
Over the past year, Biostate has continued to expand its global presence to support clinical research, data generation, and long-term operational scale.
Today, Biostate AI operates through a combination of subsidiaries and joint ventures across the United States, China, India, and the Middle East, each serving a distinct strategic role.
Global Expansion
K-Dense (US): AI data analysis platform spun out as a separate entity, focused on advanced analytics and autonomous research workflows. https://www.k-dense.ai/
Biosheng (China): Majority-owned subsidiary focused on serving the Chinese market and building local partnerships. https://www.bioshengai.com/
Baisheng (China): Joint venture with Kindstar Global (a publicly listed clinical diagnostics company:https://www.kindstar.com.cn/en) for clinical research and development on leukemia, lupus, and oral cancer.
Bayosthiti (India): Majority-owned subsidiary supporting clinical research and scalable operations in the Indian market. https://bayosthiti.ai/
Biostate MENA (Saudi Arabia): Majority-owned subsidiary focused on partnerships and population-scale opportunities across the Middle East.
Geras (US): Fully-owned subsidiary for owning real estate that will become Biostate’s ISO 13485 manufacturing facility.
With this global structure, we work closely with patients and clinical partners in each region and are prepared to scale further over time.
Thank you for being part of this journey. Simply reply to this email if you would like to talk.
Best regards,
The Biostate AI Team
https://www.biostate.ai/
